Hyperfractionated Radiotherapy and Concomitant Cisplatin for Locally Advanced Laryngeal and Hypopharyngeal Carcinomas: Final Results of a Single Institutional Program

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 6, 2003, Pages 550-557

  Arias De La Vega, Fernando ^a   Vera Garcia R ^a   Domínguez, Domínguez ^a   Villafranca Iturre, E ^a   Martinez Lopez E ^a   Miquelez Alonso, S ^a   Romero, P ^a   Medina Sola, J ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Chemoradiotherapy; Larynx cancer

Indexed keywords

ALPHA2A INTERFERON; AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; KERATINOCYTE GROWTH FACTOR; RADIOPROTECTIVE AGENT; RETINOIC ACID; TAXANE DERIVATIVE;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DYSPHONIA; EPITHELITIS; FEBRILE NEUTROPENIA; FEMALE; FIBROSIS; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OTITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGNOSIS; RADIATION DOSE FRACTIONATION; SECOND CANCER; SKIN INFLAMMATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0346874289     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000037741.09729.F4     Document Type: Article

References (69)

1. Vokes EE, Weichselbaum RR, Lippman S, et al. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Paccagnell A, Orlando A, Marcniori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui tumori della Testa e del collo. J Natl Cancer Inst 1994;86:265-72.
3. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program. J Clin Oncol 1990;18:838-47.
4. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
5. Fletcher G, Lindberg R, Hamberger H, et al. Reasons for irradiation failure in squamous cell carcinoma of the larynx. Laryngoscope 1975; 85:987-92.
6. Vokes EE, Weichselbaum RR, Lippman S, et al. Head and neck cancer. N Engl J Med 1993;328:184-94.
7. Vokes EE, Athanasiadis I. Chemotherapy for head and neck cancers: the future is now. Ann Oncol 1996;7:15-29.
8. Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer: larynx preservation and cancer chemoprevention - The Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993;53:5113-20.
9. Pignon JP, Bourhis J, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
10. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
11. Lefebvre J-L, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial - EORTC Head and Neck Cancer Cooperative Group. Natl Cancer Inst 1996;88:890-9.
12. Lefebvre JL, Wolf G, Luboinski B, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (2) Larynx preservation using neoadjuvant chemotherapy (CT) in laryngeal and hypopharyngeal carcinoma [Abstract]. Proc Am Soc Clin Oncol 1998;17:382a.
13. Bourhis J, Pignon JP, Designe L, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (1) Loco-regional treatment vs same treatment + chemotherapy (CT) [Abstract 1486]. Proc Am Soc Clin Oncol 1998;17:386a.
14. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. Clin Oncol 1990;8:911-34.
15. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1887;19:567-75.
16. Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648-53.
17. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997;15:268-76.
18. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583-9.
19. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.
20. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
21. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310-7.
22. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999;2081-6.
23. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990;8:911-34.
24. Carde P, Laval F. Effects of cis-dichlorodiammineplatinum and x-rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981;7:929-33.
25. Dewit L. Combined treatment of radiation and cis-diamminedichloro-platinum (II). A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987;13:403-26.
26. Richmond RC, Powers EL. Radiation sensitization of bacterial spores by cis-dichlorodiammineplatinum. Radiat Res 1976;68:251-7.
27. Richmond RC. Toxic variability and radiation sensitization by dichlorodiammineplatinum complexes in Salmonella typhimurium cells. Radiat Res 1984;99:596-608.
28. Wodinsky I, Swiniarski J, Kensler CJ. Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo. Cancer Chemother Rep 1974;4:73-80.
29. Zak M, Drownick J. Effects of cis-dichlodiammineplatinum with x-rays. Strahlenther Onkol 1971;142:112-5.
30. Begg A, Van der Kolk PJ, Dewit L. Radiosensitization by cisplatin on R1F1 tumor cells in vitro. Int J Radiat Oncol Biol Phys 1986;50:871-84.
31. Dritschillo A, Piro AJ, Kellman AD. The effects of cis-platinum on the repair of radiation damage in plateau phase Chinese hamster (V79) cells. Int J Radiat Oncol Biol Phys 1979;5:1345-9.
32. Adelstein DJ, Sharan VM, Earle AS, et al. The long-term results after simultaneous chemoradiotherapy for locally confined squamous cell head and neck cancer. Am J Clin Oncol 1990;13:440-7.
33. Denham JW, Abbott RL. Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity. J Clin Oncol 1991;9:458-63.
34. Dimeri IW, Homg WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
35. Gasparini G, Recher G, Testolin E, et al. Synchronous radiotherapy and chemotherapy with cisplatin in the management of locally advanced or recurrent head and neck cancer. Am J Clin Oncol 1992;15:242-9.
36. Haselow R, Warshaw MG, Oken M. Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. Head Neck Cancer 1990;2:279-81.
37. Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 1990;66:1861-8.
38. Merlano M, Corvo R, Margarino G, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck: the final report of a randomized trial. Cancer 1992;67: 915-21.
39. Taylor S, Murthy AK, Calderelli DD, et al. Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J Clin Oncol 1989;7:846-56.
40. Forastiere AA, Bellibeau JF, Goren MO, et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res 1988;48:3869-74.
41. Withers HR. Biologic basis for altered fractionation schemes., Cancer 1985;55:2086-96.
42. Ang KK, Peter LJ, Webwe RS, et al. Concomitant boost radiotherapy schedules in the treatment of the carcinomas of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990;19:1339-45.
43. Dische S, Saunders MI. The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART). Int Radiat Oncol Biol Phys 1990; 19:1317-20.
44. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 1990;8:838-47.
45. Abitbol AA, Schawade JG, Lewin AA, et al. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. Am J Clin Oncol 1992;15:250-5.
46. Choi KN, Rotman M, Aziz H, et al. Locally advanced paranasal sinus and nasopharynx tumors treated with hyperfractionated radiation and concomitant infusion cisplatin. Cancer 1991;67:2748-52.
47. Fontanesi J, Beckford NS, Lester EP, et al. Concomitant cisplatin and hyperfractionated external beam irradiation for advanced malignancy of the head and neck. Ann J Surg 1991;162:393-6.
48. Glanzmann C, Lutolf UM. Follow up data of our pilot study on concomitant hyperfractionated radiotherapy and cisplatinum (CDDP) in patients with advanced cancer of the head and neck. Strahlenther Onkol 1992;168:453-6.
49. Harrison LB, Pfister DG, Shah JP, et al. Concomitant chemo-radiation therapy for advanced unresectable head and neck cancer. Int J Radiat Oncol Biol Phys 1991;21:703-8.
50. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
51. Arias F, Dominguez MA, Illarramendi JJ, et al. Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. Int J Radiat Oncol 1995;33:675-82.
52. American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: JB Lippincott, 1997.
53. Wang CC, Blitzer PH, Suit HD. Twice-a-day radiation therapy for cancer of the head and neck. Cancer 1985;55(suppl 9):2100-104.
54. Wang CC. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation schemes. Int J Radiat Oncol Biol Phys 1988;14: 1143-6.
55. Wang CC, Suit HD, Blitzer PH. Twice-day radiation therapy for supraglottic carcinoma. Int J Radiat Oncol Biol Phys 1986;12:3-7.
56. Lowe VJ, Boyd JH, Dunphi FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651-8.
57. a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
58. Temam S, Flahaut A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385-90.
59. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p51 and p27 in laryngeal cancer. J Clin Oncol 1999;17:3150-9.
60. Veltmant JA, Bot FJ, Huynen FC, et al. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol 2000;18:1644-51.
61. Vokes EE, Kies MS, Haraf D, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-61.
62. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: preliminary results of RTOG 9003 [Abstract 1]. Int J Radiat Oncol Biol Phys 1999; 45(suppl)145.
63. Vokes EE, Pajak TF. Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. Ann Oncol 1998;9:471-4.
64. Eisbruch A, Shewach D, Bradford C, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. riCO. JCO 2001;19:792-9.
65. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-73.
66. Sunwoo J, Herscher L, Kroog G, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001;19:800-11.
67. Robert F, Ezekiel M, Spencer S, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
68. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30. A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
69. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:1008-19.